Alzheimer’s disease (AD) is the most common form of dementia, and causes a progressive decline in memory, language, executive and visuospatial function, personality and behaviour. For many years, there have been only four approved medications to improve cognition in patients with AD, but these only address the symptoms, and do not affect the course of the underlying disease. touchNEUROLOGY interviewed Professor Jeffrey Cummings, regarding the role of inflammation in AD and about the upcoming GREEN MEMORY study, a global randomised clinical trial investigating the use of GV-971 (sodium oligomannate) for the treatment of AD. Jeffrey Cummings is the director of the Chambers-Grundy Center for Transformative Neuroscience. He was a founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and served as director of the Mary S. Easton Center for Alzheimer’s Disease Research and the Deane F. Johnson Center for Neurotherapeutics, at the University of California, Los Angeles. He is a world-renowned Alzheimer’s disease researcher and leader of clinical trials, with expertise in neuropsychiatric assessment, clinical trials, developing new therapies for brain diseases and the interface of neuroscience and society. You can view the full interview, here: https://touchneurology.com/alzheimers-disease-dementia/journal-articles/the-potential-role-of-inflammation-in-alzheimers-disease/
